-
World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years
prnasia
June 28, 2021
Proteomics International Laboratories Ltd announces testing for diabetic kidney disease with the PromarkerD prognostic blood test could save US payers almost USD400 billion over 10 years, research suggests.
-
Thermo Fischer Scientific Collaborates with Protein Metrics
contractpharma
March 23, 2021
Thermo Fisher Scientific, a leader in serving science, and Protein Metrics, a developer of software tools for protein characterization, have entered into a non-exclusive co-marketing agreement to provide advanced mass spectrometry data processing and ...
-
UK Biobank unveils studies to measure circulating protein concentrations
pharmaceutical-technology
December 09, 2020
UK Biobank has announced that a consortium of ten biopharma companies will conduct a study to analyse circulating concentrations of almost 1,500 plasma proteins in around 53,000 of its participants.
-
Abcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability
prnasia
January 06, 2020
Abcam plc, a global innovator in life science reagents and tools, is pleased to announce the successful completion of the acquisition of Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences, as of 1st January 2020.
-
Proteomics research advanced by use of AI
europeanpharmaceuticalreview
May 31, 2019
Researchers succeed in using machine learning to make the mass analysis of proteins faster and almost error-free.
-
Proteomics launches diagnostic test leader ‘PromarkerD’
biospectrumasia
March 21, 2018
Proteomics International is engaged with potential partners to bring PromarkerD to market in mainland USA, Mexico, Japan, Australia, China and Europe.
-
Bioconjugation specialist Innova Biosciences acquired by SYGNIS AG
pharmaasia
August 01, 2017
Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, has announced it has been fully acquired by SYGNIS AG, for EUR 8 million in cash and 3.5 million in shares.